CELZ Receives Nasdaq Bid-Price Deficiency Notice, Has Until May 10, 2027 to Recover
CELZ is trading near its 52-week low of $0.528 (0.0% above the low) on light trading volume (0.2× avg).
Summary
A Nasdaq notice puts CELZ out of compliance after its bid price stayed under $1.00 for 30 consecutive business days, opening a 180-day cure period that ends May 10, 2027. At $0.5281, the stock needs a near-doubling or a reverse split to get back above the threshold.
Key Events · Legal and Risk Events · CELZ
-
Nasdaq Bid-Price Deficiency Notice
Nasdaq notified CELZ on November 10, 2026 that it was out of compliance with Listing Rule 5550(a)(2), the closing bid price having been below $1.00 per share for 30 consecutive business days.
-
180-Day Cure Period to May 10, 2027
CELZ has until May 10, 2027 to close at $1.00 or more for a minimum of ten consecutive business days; a further 180-day period may be available if it meets Nasdaq Capital Market initial listing standards.
-
Price Gap to Compliance Threshold
With the stock at $0.5281 against the $1.00 minimum bid, compliance requires roughly a 90% price increase absent a reverse split.
-
No Immediate Listing Impact
The notice has no immediate effect on the Nasdaq listing; the company said it will monitor the bid price and consider options to regain compliance.
Analysis · CELZ · Life Sciences
The listing now sits under formal deficiency after Nasdaq notified CELZ on November 10, 2026 that its closing bid had stayed below $1.00 for 30 straight business days. With the stock at $0.5281 today, roughly half the threshold, regaining compliance would take a near-doubling of the share price or a reverse split. The company has until May 10, 2027, and a possible second 180-day window if it meets Nasdaq Capital Market initial listing standards. Given a $5.58M nine-month net loss against a $6.85M cash balance, a reverse split is the most likely mechanical fix, and it would come on top of the dilution already authorized by the August 2026 shareholder vote to raise authorized shares to 100 million.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELZ was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.53 to $4.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.